Morgan Stanley lowered the firm’s price target on Amicus to $18 from $19 and keeps an Overweight rating on the shares. The firm’s estimates are in line with consensus on Galafold revenues and Pombiliti plus Opfolda revenues, the analyst tells investors in a preview note. The firm will be looking out for updates on the Pombiliti plus Opfolda launch and whether the company is tracking to full-year non-GAAP profitability, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue